GlassScriptPhysician profile
Emily Hale
NPI 1083247308
$3,471.77
in general payments reported to CMS, 2019-2025
27 companies · $1,889 in 2025
The $1,889 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $544 · 2024: $1,039 · 2025: $1,889.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,472.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,471.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scilex Pharmaceuticals INC. | $786.09 | 2023-2025 | Ztlido |
| Collegium Pharmaceutical, INC. | $426.57 | 2024-2025 | Belbuca, Xtampza |
| Abbvie INC. | $309.41 | 2024-2025 | |
| Nevro Corp. | $296.95 | 2023 | Senza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $275.99 | 2024-2025 | Relistor |
| Forte Bio-Pharma LLC | $211.70 | 2023-2024 | Prolate, Nalocet |
| Neurocrine Biosciences, INC. | $181.81 | 2024-2025 | Ingrezza |
| Valinor Pharma, LLC | $90.02 | 2024-2025 | Movantik |
| Lilly USA, LLC | $85.44 | 2024-2025 | Emgality |
| Pfizer INC. | $78.60 | 2024-2025 | |
| Boston Scientific Corporation | $77.47 | 2023 | |
| Lundbeck LLC | $75.39 | 2025 | Vyepti |
| Vertex Pharmaceuticals Incorporated | $74.93 | 2025 | |
| Curonix LLC | $71.40 | 2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Ucb, INC. | $69.09 | 2024 | Briviact |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $47.48 | 2025 | Uplizna |
| Axsome Therapeutics, INC. | $40.21 | 2025 | Symbravo, Sunosi |
| Tg Therapeutics, INC. | $40.06 | 2025 | |
| Neurelis, INC. | $35.93 | 2025 | Valtoco |
| Abbott Laboratories | $34.87 | 2025 | Eterna |
| Inspire Medical Systems, INC. | $32.26 | 2025 | Inspire |
| Medtronic, INC. | $29.48 | 2024 | Intellis Adaptivestim |
| Emd Serono, INC. | $23.52 | 2025 | |
| Genentech USA, INC. | $21.12 | 2025 | Ocrevus Zunovo |
| Biogen, INC. | $20.43 | 2025 | Vumerity |
| Novartis Pharmaceuticals Corporation | $19.39 | 2025 | |
| Nalu Medical, INC. | $16.16 | 2024 | Nalu Neurostimulation System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Hale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.